Expression and prognostic role of syndecan-2 in prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 1, 2010, Pages 78-82

  Popovi, A ^a   Demirovi, A ^b   Spaji, B ^a   Timac, G ^a   Krulin, B ^b,c   Tomas, D ^b,c  

^a University Department of Urology   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Prognosis; Syndecan 2

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SYNDECAN 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELLULAR DISTRIBUTION; DISEASE FREE SURVIVAL; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SYNDECAN-2; TUMOR MARKERS, BIOLOGICAL;

EID: 76949096161     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.43     Document Type: Article

References (22)

1. Rapraeger AC. Syndecan-regulated receptor signaling. J Cell Biol 2000; 149: 995-998.
2. Essner JJ, Chen E, Ekker SC. Syndecan-2. Int J Biochem Cell Biol 2006; 38: 152-156.
3. Simons M, Horovitz A. Syndecan-4-mediated signaling. Cell Signal 2001; 13: 855-866.
4. Woods A, Couchman JR. Syndecan-4 and focal adhesion function. Curr Opin Cell Biol 2001; 13: 578-583.
5. Choi S, Lee E, Kwon S, Park H, Yi JY, Kim S et al. Transmembrane domain-induced oligomerization is crucial for the functions of syndecan-2 and syndecan-4. J Biol Chem 2005; 280: 42573-42579.
6. Noguer O, Villena J, Lorita J, Vilaro S, Reina M. Syndecan-2 downregulation impairs angiogenesis in human microvascular endothelial cells. Exp Cell Res 2009; 315: 795-808.
7. Marynen P, Zhang J, Cassiman JJ, Van den Berghe H, David G. Partial primary structure of the 48- and 90-kilodalton core proteins of cell surface-associated heparan sulfate proteoglycans of lung fibroblasts. Prediction of an integral membrane domain and evidence for multiple distinct core proteins at the cell surface of human lung fibroblasts. J Biol Chem 1989; 264: 7017-7024.
8. Tkachenko E, Rhodes JM, Simons M. Syndecans: new kids on the signaling block. Circ Res 2005; 96: 488-500.
9. Han I, Park H, Oh ES. New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J Mol Histol 2004; 35: 319-326.
10. Huang JW, Chen CL, Chuang NN. P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005; 329: 855-862.
11. Kim Y, Park H, Lim Y, Han I, Kwon HJ,Woods A et al. Decreased syndecan-2 expression correlates with trichostatin-A-induced morphological changes and reduced tumorigenic activity in colon carcinoma cells. Oncogene 2003; 22: 826-830.
12. Choi S, Kim Y, Park H, Han IO, Chung E, Lee SY et al. Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2. Biochem Biophys Res Commun 2009; 384: 231-235.
13. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003; 199: 479-487.
14. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002; 277: 29730-29736.
15. Huang X, Xiao DW, Xu LY, Zhong HJ, Liao LD, Xie ZF et al. Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma. Oncol Rep 2009; 21: 1123-1239.
16. Contreras HR, Ledezma RA, Vergara J, Cifuentes F, Barra C, Cabello P et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol 2009. May 16. [Epub ahead of print], PMID:19450993, doi:10.1016/j.urolonc.2009.03.018.
17. Sobin LH, Wittekind C (eds) International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 5th edn. Wiley Liss: New York, USA, 1997. pp 170-173.
18. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003; 55: 20-29.
19. Shariat SF, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI et al. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int 2008; 101: 232-237.
20. Kiviniemi J, Kallajoki M, Kujala I, Matikainen MT, Alanen K, Jalkanen M et al. Altered expression of syndecan-1 in prostate cancer. APMIS 2004; 112: 89-97.
21. Chen D, Adenekan B, Chen L, Vaughan ED, Gerald W, Feng Z et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004; 63: 402-407.
22. Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Konishi N. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci 2009. April 21. [Epub ahead of print], PMID:19432893, doi:10.1111/j.1349-7006.2009.01174.